Composition comprising tetracyclic compound

Abstract

a pharmaceutically acceptable carrier, and a dissolution aid.is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.

1 - 12 . (canceled) 
     
     
         13 . A composition comprising 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile,
 or a salt thereof, a pharmaceutically acceptable carrier, and a dissolution aid,   wherein the dissolution aid is selected from the group consisting of citric acid, hydroxypropylmethyl cellulose, methacrylic acid copolymer LD, methyl cellulose, purified shellac, sodium dehydroacetate, fumaric acid, DL-malic acid, L-aspartic acid, adipic acid, propylene glycol alginate ester, sodium caseinate, carboxymethylethyl cellulose, succinic acid, copolyvidone, dioctyl sodium sulfosuccinate, lactic acid, aluminum lactate, hydroxyethylmethyl cellulose, hydroxypropylmethyl cellulose acetate succinate, sodium polystyrene sulfonate, polyvinylacetal diethylaminoacetate, methacrylic acid copolymer S, sulfuric acid, aluminum sulfate, a vinyl pyrrolidone x vinyl acetate copolymer, and sodium decyl sulfate.   
     
     
         14 . The composition according to  claim 13 , wherein the composition further comprises an organic polymer which is selected from the group consisting of hydroxypropyl cellulose, powdered agar, guar gum, zein, a carboxyvinyl polymer, polyvinyl alcohol, a vinyl acetate resin, casein, amino alkylmethacrylate copolymer E, cellulose acetate phthalate, and a mixture thereof. 
     
     
         15 . The composition according to  claim 13 , wherein said 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or salt thereof has a water solubility less than 100 μg/mL at 25° C. 
     
     
         16 . An orally administrable formulation comprising the composition of  claim 13 .